![](https://xpic.x-mol.com/20231120%2F1700470731880.jpg)
教育背景及工作经历
2007.09 – 2011.07 沈阳药科大学 环境科学理学学士
2012.09 – 2015.07 沈阳药科大学 药物化学硕士 师从陈国良教授
2015.07 – 2016.09 沈阳药科大学陈国良教授课题组从事药物合成工作
2016.09 – 2019.07 沈阳药科大学 药物化学博士 师从陈国良教授
2020.11 – 2021.01 南方科技大学张绪穆课题组 访问学者
2021.01 – 2023.01 南方科技大学博士后 合作导师:张绪穆院士
2023.01 – 2023.11 南方科技大学坪山生物医药研究院 研发主任
2023.11 – 至今 南方科技大学化学系研究助理教授 合作导师:张绪穆院士
代表性文章 (近5年)
1.Qifan Zhou1 , Sidi Yang1 , Liu Cao1 , Qishu Chen1 , Yang Yang1 , Tiefeng Xu1 , Hongzhou Lu*, Yingjun Li*, Deyin Guo*, and Xumu Zhang*. Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: An oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduction and Targeted Therapy, 2023, 8, 27. (IF: 38.104)
2.Qifan Zhou1 , Yinzhu Luo1 , Yujun Zhu1 , Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249, 115113. (IF = 7.088)
3.Liu Cao1 , Yingjun Li1 , Sidi Yang1 , Guanguan Li1 , Qifan Zhou1 , Jing Sun1 , et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. (Co-author, IF=17.956)
4.Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis andbiological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. (IF = 3.925)
5.Fangyu Du1 , Qifan Zhou1 , Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083. (IF = 4.927)
6.Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N‑arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. (IF = 4.198)
7.Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. (IF = 2.032)
8.Chunling Yuan1 , Xiaoli Guo1 , Qifan Zhou1 , Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing <beta>-amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. (IF = 6.633)
9.Yajie Shi1 , Qifan Zhou1 , Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. (IF = 2.032)
10.Fangyu Du1 , Qifan Zhou1 , Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168 (IF = 2.170)
11.Fangyu Du1 , Qifan Zhou1 , Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6- dimethylpyridin-2-yl)carbonate as a green and chemoselective N-tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43(17), 6549–6554. (IF = 3.925)
12.Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9(5), 2498–2508. (IF = 4.036)
13.Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11(7), 398–420. (IF = 5.247)
14.Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49(4), 576–586. (IF = 1.937)
15.Caijiao Wu1 , Qifan Zhou1 , Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43(11-12), 480-485.(IF = 1.097)
16.Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151(5), 39-50. (IF = 7.088)
17.Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23(7), 1784-1798. (IF = 4.927)
18. Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42(8), 395-446. (IF = 1.097)
19.Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl- 1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42(12), 608–610. (IF = 1.097)
20.Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29(06), 779-784. (IF = 2.170)
22.另外,以第一、二作者发表的中文核心近十篇,主要杂志包括《药学学报》、《沈阳药科大学学报》、《精细化工》、《解剖科学进展》等。
代表性专利 (近 5 年)
- 周启璠, 陈奇妹, 李迎君, 张绪穆。非甾体抗炎药和 GS-441524 的二联体化合物及其制备方法与用途。2023,CN116178373A。
- 李 迎 君 , 曹 流 , 周启璠 , 郭 德 银 , 张 绪 穆 。 一 种 核 苷 类 化 合 物 及 其 用 途 。 2021 , CN114292272A,WO2022143473 A1。
- 张绪穆, 郭德银, 李官官, 曹流, 李迎君, 徐铁凤, 冀彦锡, 周启璠, 杨彧鉴, 朱调珍。一种治疗病毒感染的核苷类化合物及其用途。2021,CN113735862A。
- 李迎君, 李官官, 周启璠, 张绪穆。一种核苷类化合物的晶型及其制备方法。2021,CN113698405A (已授权)。
- 李迎君, 周启璠, 杨彧鉴, 李官官, 张绪穆。一种核苷类化合物的制备方法。2021,CN113754665A (已授权)。
- 陈国良, 伍英, 包雪飞, 李国华, 梁昕杰, 姜士宽, 周启璠, 杜芳瑜。白坚木皮醇在铜催化芳基卤代物水解反应中的应用。2021,CN109970542A (已授权)。
- 陈国良, 周启璠, 杜芳瑜, 杜洋, 石雅洁, 方婷, 周林波。BBI608 衍生物及其制备与用途。2021,CN107973788A (已授权)。
- 陈国良, 包雪飞, 周启璠, 刘子奥, 高勋。阿哌沙班衍生物及其制备方法和用途。2021,CN107400131A (已授权)。
- 陈国良, 杜芳瑜, 刘中博, 周启璠, 孙文娇, 傅扬。一种 sEH 抑制剂及其制备方法和应用。2020,CN111423396A (已授权)。
- 陈国良, 王立辉, 周启璠, 杜芳瑜, 董晓雨, 杨静玉, 吴春福。吡咯-3-甲酰胺类化合物及其制备方法和用途。2020,CN109320499A (已授权)。
- 陈国良, 杨静玉, 杜芳瑜, 周启璠, 方武宏, 王立辉, 吴春福。2,2-二甲基苯并吡喃类衍生物及其制备方法和用途。2018,CN109096235A (已授权)。
- 吴春福, 王立辉, 杨静玉, 陈国良, 李猛, 蒋晓蕊, 李华欢, 周启璠, 方武宏。一种查尔酮类化合物在制备抗血管新生药物中的用途。2018,CN104473917A (已授权)。